What Is Eupraxia Pharmaceuticals Inc. (EPRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Eupraxia Pharmaceuticals Inc. at its current price of $6.43. The composite intrinsic value is estimated at $4.66 (-27.6% average return), with 4 models flagging overvaluation risk. Notably, First Chicago sees the most upside at +54.4% (fair value: $9.92), while Dynamic NAV is the most conservative at -86.4% ($0.87). The spread between these extremes — +140.8% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About EPRX?
7 of 13 models are currently active for EPRX. Of these, 2 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates EPRX's intrinsic value at $1.72, implying -73.3% downside from the current price. See which stocks rank higher →
How Does EPRX Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, EPRX ranks #412 by Quality of Company score. CirclFi's QOC score of 2.2/10 evaluates 32 fundamental signals. A score of 2.2 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Eupraxia Pharmaceuticals Inc. competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is EPRX a Value Trap?
CirclFi's Value Trap algorithm assigns EPRX a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Eupraxia Pharmaceuticals Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Eupraxia Pharmaceuticals Inc. is rated at 2.2/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.
The gap between the most bullish and bearish model spans +140.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every EPRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across EPRX's 7 active models, average confidence is 8%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad